Track Harbin Pharmaceutical Group , Ltd.'s EBIT ($940M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest EBIT for 600664.SS is $940M as of September 2026. That compares with $650M in the prior-year period — up 44.0% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Harbin Pharmaceutical Group , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, 600664.SS's EBIT moved from $650M to $940M — a 44.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harbin Pharmaceutical Group , Ltd.'s operating scale or balance-sheet position.
Against its sector companies, 600664.SS currently prints $940M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Harbin Pharmaceutical Group , Ltd.'s growth, margins, and balance sheet.
A EBIT figure of $940M for 600664.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.
After noting 600664.SS's EBIT ($940M), review year-over-year change from $650M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.